| Sonstiges: |
- Nachgewiesen in: MEDLINE
- Sprachen: English
- Publication Type: Journal Article
- Language: English
- [Eur J Heart Fail] 2022 Jan; Vol. 24 (1), pp. 1-3.
- MeSH Terms: Cardiac Resynchronization Therapy* ; Heart Failure* / diagnosis ; Heart Failure* / therapy ; Europe ; Humans ; Stroke Volume
- References: McDonagh TA, Metra M, Adamo M, Gardner RS, Baumbach A, Bohm M, et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur J Heart Fail. 2022;24:4-131. ; Crespo-Leiro MG, Metra M, Lund LH, Milicic D, Costanzo MR, Filippatos G, et al. Advanced heart failure: a position statement of the Heart Failure Association of the European Society of Cardiology. Eur J Heart Fail. 2018;20:1505-35. ; Mullens W, Damman K, Harjola VP, Mebazaa A, Brunner-La Rocca HP, Martens P, et al. The use of diuretics in heart failure with congestion - a position statement from the Heart Failure Association of the European Society of Cardiology. Eur J Heart Fail. 2019;21:137-55. ; Mullens W, Auricchio A, Martens P, Witte K, Cowie MR, Delgado V, et al. Optimized implementation of cardiac resynchronization therapy: a call for action for referral and optimization of care: a joint position statement from the Heart Failure Association (HFA), European Heart Rhythm Association (EHRA), and European Association of Cardiovascular Imaging (EACVI) of the European Society of Cardiology. Eur J Heart Fail. 2020;22:2349-69. ; Mullens W, Damman K, Testani JM, Martens P, Mueller C, Lassus J, et al. Evaluation of kidney function throughout the heart failure trajectory - a position statement from the Heart Failure Association of the European Society of Cardiology. Eur J Heart Fail. 2020;22:584-603. ; Chioncel O, Parissis J, Mebazaa A, Thiele H, Desch S, Bauersachs J, et al. Epidemiology, pathophysiology and contemporary management of cardiogenic shock - a position statement from the Heart Failure Association of the European Society of Cardiology. Eur J Heart Fail. 2020;22:1315-41. ; Seferović P, Fragasso G, Petrie M, Mullens W, Ferrari R, Thum T, et al. Heart Failure Association of the European Society of Cardiology update on sodium-glucose co-transporter 2 inhibitors in heart failure. Eur J Heart Fail. 2020;22:1984-6. ; Seferović P, Coats A, Ponikowski P, Filippatos G, Huelsmann M, Jhund P, et al. European Society of Cardiology/Heart Failure Association position paper on the role and safety of new glucose-lowering drugs in patients with heart failure. Eur J Heart Fail. 2020;22:196-213. ; Seferovic PM, Tsutsui H, McNamara DM, Ristic AD, Basso C, Bozkurt B, et al. Heart Failure Association of the ESC, Heart Failure Society of America and Japanese Heart Failure Society Position statement on endomyocardial biopsy. Eur J Heart Fail. 2021;23:854-71. ; Bozkurt B, Coats AJS, Tsutsui H, Abdelhamid CM, Adamopoulos S, Albert N, et al. Universal definition and classification of heart failure: a report of the Heart Failure Society of America, Heart Failure Association of the European Society of Cardiology, Japanese Heart Failure Society and Writing Committee of the Universal Definition of Heart Failure: Endorsed by the Canadian Heart Failure Society, Heart Failure Association of India, Cardiac Society of Australia and New Zealand, and Chinese Heart Failure Association. Eur J Heart Fail. 2021;23:352-80. ; Rosano GMC, Moura B, Metra M, Bohm M, Bauersachs J, Ben Gal T, et al. Patient profiling in heart failure for tailoring medical therapy. A consensus document of the Heart Failure Association of the European Society of Cardiology. Eur J Heart Fail. 2021;23:872-81. ; Aktaa S, Polovina M, Rosano G, Abdin A, Anguita M, Lainscak M, et al. European Society of Cardiology quality indicators for the care and outcomes of adults with heart failure. Developed by the Working Group for Heart Failure Quality Indicators in collaboration with the Heart Failure Association of the European Society of Cardiology. Eur J Heart Fail. 2022;24:132-42. ; Piepoli MF, Adamo M, Barison A, Bestetti RB, Biegus J, Böehm M, et al. Preventing heart failure: a position paper of the Heart Failure Association in collaboration with the European Association of Preventive Cardiology. Eur J Heart Fail. 2022;24:143-68. ; Vaduganathan M, Pareek M, Kristensen AMD, Biering-Sorensen T, Byrne C, Almarzooq Z, et al. Prevention of heart failure events with intensive versus standard blood pressure lowering across the spectrum of kidney function and albuminuria: a SPRINT substudy. Eur J Heart Fail. 2021;23:384-92. ; Bhatia K, Jain V, Gupta K, Bansal A, Fox A, Qamar A, et al. Prevention of heart failure events with sodium-glucose co-transporter 2 inhibitors across a spectrum of cardio-renal-metabolic risk. Eur J Heart Fail. 2021;23:1002-8. ; Butler J, Handelsman Y, Bakris G, Verma S. Use of sodium-glucose co-transporter-2 inhibitors in patients with and without type 2 diabetes: implications for incident and prevalent heart failure. Eur J Heart Fail. 2020;22:604-17. ; Shin SH, Claggett B, Pfeffer MA, Skali H, Liu J, Aguilar D, et al. Hyperglycaemia, ejection fraction and the risk of heart failure or cardiovascular death in patients with type 2 diabetes and a recent acute coronary syndrome. Eur J Heart Fail. 2020;22:1133-43. ; Wei D, Li J, Janszky I, Chen H, Fang F, Ljung R, et al. Death of a child and the risk of heart failure: a population-based cohort study from Denmark and Sweden. Eur J Heart Fail. 2022;24:181-9. ; Adler ED, Voors AA, Klein L, Macheret F, Braun OO, Urey MA, et al. Improving risk prediction in heart failure using machine learning. Eur J Heart Fail. 2020;22:139-47. ; Segar MW, Khan MS, Patel KV, Vaduganathan M, Kannan V, Willett D, et al. Incorporation of natriuretic peptides with clinical risk scores to predict heart failure among individuals with dysglycaemia. Eur J Heart Fail. 2022;24:169-80. ; Meijers WC, Bayes-Genis A, Mebazaa A, Bauersachs J, Cleland JGF, Coats AJS, et al. Circulating heart failure biomarkers beyond natriuretic peptides: review from the Biomarker Study Group of the Heart Failure Association (HFA), European Society of Cardiology (ESC). Eur J Heart Fail. 2021;23:1610-32. ; Castiglione V, Franzini M, Aimo A, Carecci A, Lombardi CM, Passino C, et al. Use of biomarkers to diagnose and manage cardiac amyloidosis. Eur J Heart Fail. 2021;23:217-30. ; Becher PM, Schrage B, Benson L, Fudim M, Corovic Cabrera C, Dahlstrom U, et al. Phenotyping heart failure patients for iron deficiency and use of intravenous iron therapy: data from the Swedish Heart Failure Registry. Eur J Heart Fail. 2021;23:1844-54. ; Tkaczyszyn M, Comin-Colet J, Voors AA, van Veldhuisen DJ, Enjuanes C, Moliner P, et al. Iron deficiency contributes to resistance to endogenous erythropoietin in anaemic heart failure patients. Eur J Heart Fail. 2021;23:1677-86. ; Graham FJ, Masini G, Pellicori P, Cleland JGF, Greenlaw N, Friday J, et al. Natural history and prognostic significance of iron deficiency and anaemia in ambulatory patients with chronic heart failure. Eur J Heart Fail. 2021. https://doi.org/10.1002/ejhf.2251. ; Alnuwaysir RIS, Grote Beverborg N, Hoes MF, Markousis-Mavrogenis G, Gomez KA, van der Wal HH, et al. Additional burden of iron deficiency in heart failure patients beyond the cardio-renal anaemia syndrome: findings from the BIOSTAT-CHF study. Eur J Heart Fail. 2022;24:192-204. ; Cooper LB, Benson L, Mentz RJ, Savarese G, DeVore AD, Carrero JJ, et al. Association between potassium level and outcomes in heart failure with reduced ejection fraction: a cohort study from the Swedish Heart Failure Registry. Eur J Heart Fail. 2020;22:1390-8. ; Ferreira JP, Mogensen UM, Jhund PS, Desai AS, Rouleau JL, Zile MR, et al. Serum potassium in the PARADIGM-HF trial. Eur J Heart Fail. 2020;22:2056-64. ; Butler J, Anker SD, Siddiqi TJ, Coats AJS, Dorigotti F, Filippatos G, et al. Patiromer for the management of hyperkalaemia in patients receiving renin-angiotensin-aldosterone system inhibitors for heart failure: design and rationale of the DIAMOND trial. Eur J Heart Fail. 2022;24:230-8. ; Rosenkranz S, Channick R, Chin KM, Jenner B, Gaine S, Galie N, et al. The impact of comorbidities on selexipag treatment effect in patients with pulmonary arterial hypertension: insights from the GRIPHON study. Eur J Heart Fail. 2021. https://doi.org/10.1002/ejhf.2369. ; Kimmoun A, Takagi K, Gall E, Ishihara S, Hammoum P, El Beze N, et al. Temporal trends in mortality and readmission after acute heart failure: a systematic review and meta-regression in the past four decades. Eur J Heart Fail. 2021;23:420-31. ; Wettersten N, Horiuchi Y, van Veldhuisen DJ, Ix JH, Mueller C, Filippatos G, et al. Decongestion discriminates risk for one-year mortality in patients with improving renal function in acute heart failure. Eur J Heart Fail. 2021;23:1122-30. ; Kaplon-Cieslicka A, Benson L, Chioncel O, Crespo-Leiro MG, Coats AJS, Anker SD, et al.; Heart Failure Association (HFA) of the European Society of Cardiology (ESC) and the ESC Heart Failure Long-Term Registry Investigators. A comprehensive characterization of acute heart failure with preserved versus mildly reduced versus reduced ejection fraction - insights from the ESC-HFA EORP Heart Failure Long-Term Registry. Eur J Heart Fail. 2021. https://doi.org/10.1002/ejhf.2408. ; Lombardi C, Peveri G, Cani D, Latta F, Bonelli A, Tomasoni D, et al. In-hospital and long-term mortality for acute heart failure: analysis at the time of admission to the emergency department. ESC Heart Fail. 2020;7:2650-61. ; Rosano GMC, Vitale C, Adamo M, Metra M. Roadmap for the management of heart failure patients during the vulnerable phase after heart failure hospitalizations: how to implement excellence in clinical practice. J Cardiovasc Med (Hagerstown). 2021. https://doi.org/10.2459/JCM.0000000000001221. ; Logeart D, Berthelot E, Bihry N, Eschalier R, Salvat M, Garcon P, et al. Early and short-term intensive management after discharge for patients hospitalized with acute heart failure: a randomized study (ECAD-HF). Eur J Heart Fail. 2022;24:219-26.
- Entry Date(s): Date Created: 20220127 Date Completed: 20220401 Latest Revision: 20220401
- Update Code: 20240513
|
